October 27, 2023 04:11 AM EDTUpdated 08:13 AM
Pharma
FDA+

Eli Lil­ly’s ul­cer­a­tive col­i­tis drug ap­proved by FDA in crowd­ed mar­ket

Kyle LaHucik

Biotech Correspondent

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Bris­tol My­ers bets $1.5B on BioN­Tech's PD-L1xVEGF from Bio­theus

Sanofi to snap up Blue­print Med­i­cines and mas­to­cy­to­sis drug Ay­vak­it for $9.1B

Kymera un­veils ‘ex­cep­tion­al’ Phase 1 da­ta for its Dupix­ent-in-a-pill pro­gram

In race with Merus, Bicara makes the case for two-year sur­vival da­ta

Ve­ra posts pos­i­tive Phase 3 rare kid­ney dis­ease da­ta, but crowd­ed mar­ket looms

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times